The current role of anticoagulants in cardiovascular medicine

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis Research

Background:

• Thrombotic events in cardiovascular disease pose a significant healthcare burden.
• Anticoagulants are crucial for preventing events like stroke in atrial fibrillation and acute coronary syndrome.
• Current parenteral anticoagulants include unfractionated heparin, low-molecular-weight heparins (LMWHs), and fondaparinux.

Purpose of the Study:

• To review the current landscape of anticoagulant therapies.
• To identify the limitations of existing anticoagulant treatments.
• To highlight the unmet need for novel oral anticoagulants.

Main Methods:

• Review of current clinical guidelines and pharmacological data.
• Analysis of efficacy and safety profiles of parenteral anticoagulants.
• Evaluation of the limitations of oral anticoagulants, such as Vitamin K antagonists.

Main Results:

• LMWHs and unfractionated heparin show similar efficacy in acute coronary syndrome, with LMWHs potentially offering a better safety profile.
• Fondaparinux demonstrates significantly lower mortality in acute coronary syndrome compared to heparins.
• Parenteral anticoagulants are inconvenient for long-term outpatient use, and current oral anticoagulants have significant drawbacks.

Conclusions:

• Existing anticoagulant options have limitations in efficacy, safety, or convenience.
• A substantial unmet need exists for oral anticoagulants that are convenient, well-tolerated, and do not require routine monitoring.
• Development of new oral anticoagulants is critical for improving long-term management of thrombotic events in cardiovascular disease.